<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389867</url>
  </required_header>
  <id_info>
    <org_study_id>CL073</org_study_id>
    <nct_id>NCT03389867</nct_id>
  </id_info>
  <brief_title>Open Label Study to Evaluate the Effect of Kaempferia Parviflora in Support of Erectile Function and Male Sexual Health</brief_title>
  <official_title>An Open Label Study to Evaluate the Effect of Kaempferia Parviflora in Support of Erectile Function and Male Sexual Health Among Overall Healthy Males 50-70.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Supplement Formulators, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Supplement Formulators, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the overall efficacy and safety of Kaempferia
      parviflora in overall healthy male human subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was an open label safety and efficacy study. Each subject received a specific dose
      of a formulation containing Kaempferia parviflora. There would be attempted telephone or
      e-mail contact in 2 weeks following enrollment.

      Participants would undergo assessments of blood tests, vital signs, body weight with
      completion of questionnaires.

      The primary objective was to assess the effect of Kaempferia parviflora on erectile function
      among overall healthy males age 50 to 70.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 30, 2014</start_date>
  <completion_date type="Actual">March 15, 2016</completion_date>
  <primary_completion_date type="Actual">November 29, 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IIEF (International Index of Erectile Dysfunction) questionnaire scores</measure>
    <time_frame>30 days</time_frame>
    <description>Mean change in IIEF scores. There are five specific areas addressed including Erectile Function (questions:1-5 &amp; 15;score range: 0-5, maximum score:30); Orgasmic Function (questions:9-10; score range:0-5; maximum score:10); Sexual desire (questions:11-12; score range:1-5; maximum score:10); Intercourse satisfaction (questions:6-8; score range:0-5; maximum score:15); Overall satisfaction (questions:13-14; score range:1-5; maximum score:10). The lower the score represents greater dysfunction within each domain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GAQ (Global Assessment Question)</measure>
    <time_frame>30 days</time_frame>
    <description>Response (yes or no) from Global Assessment Question</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Free Testosterone</measure>
    <time_frame>30 days</time_frame>
    <description>Mean change in Free Testosterone levels in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Total Testosterone</measure>
    <time_frame>30 days</time_frame>
    <description>Mean change in Total Testosterone levels in ng/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Estradiol</measure>
    <time_frame>30 days</time_frame>
    <description>Mean change in Estradiol levels in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of DHEA-S</measure>
    <time_frame>30 days</time_frame>
    <description>Mean change in DHEA-S levels in ug/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of PSA</measure>
    <time_frame>30 days</time_frame>
    <description>Mean change in PSA levels in ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Total Cholesterol</measure>
    <time_frame>30 days</time_frame>
    <description>Mean change in Total Cholesterol levels in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of LDL Cholesterol</measure>
    <time_frame>30 days</time_frame>
    <description>Mean change in LDL Cholesterol levels in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of HDL Cholesterol</measure>
    <time_frame>30 days</time_frame>
    <description>Mean change in HDL Cholesterol levels in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of Triglycerides</measure>
    <time_frame>30 days</time_frame>
    <description>Mean change in Triglyceride levels in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index</measure>
    <time_frame>30 days</time_frame>
    <description>Mean change in body mass index in kg/m^2 calculated by formula using the body weight (lb.) and the height (in.)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Erectile Function</condition>
  <arm_group>
    <arm_group_label>Male Sexual Health Formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kaempferia parviflora extract 100mg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Kaempferia parviflora extract</intervention_name>
    <arm_group_label>Male Sexual Health Formulation</arm_group_label>
    <other_name>KaempMax™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria:

          1. Healthy male volunteers between the age of 50-70 inclusive

          2. Having been (or attempted to be) sexually active for at least the last 6 months

          3. Having been in a stable sexual relationship for the past 6 months or more

          4. Be able to comply with a 14-day washout period of all sexual performance enhancing
             medications, nutritional supplements or herbs prior to Day 1 randomization

          5. Be able to comply with a 14-day washout period of all nutritional supplements that may
             contain any of the components of the formulation prior to Day 1 enrollment

        Primary Exclusion Criteria:

          1. Having a Body Mass Index greater than 34.9

          2. Currently receiving or having received treatment in the past 6 months for any sexual
             disorder or dysfunction (including treatment for erectile function, intercourse
             satisfaction, orgasmic function, or sexual desire)

          3. Attain a score of &lt; 16 on the IIEF-5 questionnaire

          4. Primary diagnosis of another sexual disorder (e.g., premature ejaculation)

          5. Currently taking supplements including Kaempferia parviflora, DHEA
             (Dehydroepiandrosterone), chrysin, pregnenolone, grape seed extract, bitter orange,
             country mallow, ephedra, bitter melon, catuaba, horny goat weed, mucuna pruriens,
             maca, tribulus terrestris, muira puama, yohimbe or sativa, fenugreek, tongkat ali,
             Activali, Eurycoma longifolia Jack and goat's rue or any other supplement which has
             effects on sexual health. Also, testosterone and aromatase inhibitors (letrozole,
             anastrozole, exemestane, tesolactone) and phosphodiesterase type 5 inhibitors (e.g.
             sildenafil, tadalafil, vardenafil) unless willing to washout 14 days prior to baseline

          6. Having any of the following disorders: benign prostatic hyperplasia (BPH), diabetes
             mellitus, cancer (including prostate and male breast cancer), insomnia, sleep apnea,
             heart disease, hypertension, renal disease, liver disease, vascular disease, endocrine
             abnormalities (e.g. hypogonadism or hypo/hyperthyroidism), multiple sclerosis,
             psychiatric disorder, acute genitourinary disorder, history of spinal cord injury,
             herniated disc, penile injury or disease (e.g. Peyronie's disease, priapism or genital
             anatomic abnormalities) or any other significant medical or surgical procedure that
             precludes participation in the judgment of the investigator/sub-investigator

          7. Currently taking medications for benign prostatic hyperplasia (e.g. tamsulosin,
             dutasteride, finasteride, terazosin), theophylline medications, antihypertensive
             medications (e.g. diuretics, sympatholytics, beta blockers, calcium channel blockers),
             antidiabetic medications, psychiatric medications (e.g. antipsychotic agents,
             antidepressants, or anxiolytic agents), androgenic and antiandrogenic medications,
             digitalis, histamine H2-receptor blockers, ketoconazole, niacin, MAOI (monoamine
             oxidase inhibitor) (e.g. phenelzine), phenobarbital, phenytoin, anticoagulants (e.g.
             warfarin, high dose aspirin, cilostazol [Pletal], clopidogrel [Plavix], dalteparin
             [Fragmin], enoxaparin [Lovenox], heparin, ticlopidine [Ticlid]) or receiving nitrate
             therapy -

          8. Laboratory: bilirubin &gt; 2 x ULN (Upper limit of normal) , AST/SGOT (aspartate
             aminotransferase/serum glutamic oxaloacetic transaminase) and ALT/SGPT (alanine
             aminotransferase/serum glutamic pyruvic transaminase) ( &gt; 2 x ULN, serum creatinine &gt;
             1.5 mg/dL, total cholesterol &gt; 347.9mg/dl, triglycerides &gt; 300mg/dl, and PSA &gt; 4 ng/mL
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male</gender_description>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Joyal</last_name>
    <role>Principal Investigator</role>
    <affiliation>Life Extension</affiliation>
  </overall_official>
  <link>
    <url>http://www.wantitall.co.za/Health-and-Personal-Care/Kaempferia-Parviflora-60-capsules__B006JXOOT0</url>
    <description>Kaempferia parviflora</description>
  </link>
  <reference>
    <citation>Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999 Jul;84(1):50-6.</citation>
    <PMID>10444124</PMID>
  </reference>
  <reference>
    <citation>Chivapat S, Chavalittumrong P, Attawish A et al. Chronic Toxicity Study of Kaempferia parviflora Wall ex. Extract. Thai J Vet. Med. 40(4):377-383, 2010.</citation>
  </reference>
  <reference>
    <citation>. Report from Tokiwa Phytochemical Co. LTD. Sirtmax® PCT/JP2012/084000.</citation>
  </reference>
  <reference>
    <citation>Shabsigh R, Anastasiadis AG. Erectile dysfunction. Annu Rev Med. 2003;54:153-68. Epub 2002 Aug 19. Review.</citation>
    <PMID>12525671</PMID>
  </reference>
  <reference>
    <citation>Sudwan P, Saenphet K, Saenphet S, Suwansirikul S. Effect of Kaempferia parviflora Wall. ex. Baker on sexual activity of male rats and its toxicity. Southeast Asian J Trop Med Public Health. 2006;37 Suppl 3:210-5.</citation>
    <PMID>17547083</PMID>
  </reference>
  <reference>
    <citation>Sutthanut K, Sripanidkulchai B, Yenjai C, Jay M. Simultaneous identification and quantitation of 11 flavonoid constituents in Kaempferia parviflora by gas chromatography. J Chromatogr A. 2007 Mar 2;1143(1-2):227-33. Epub 2007 Jan 13.</citation>
    <PMID>17266972</PMID>
  </reference>
  <reference>
    <citation>Tambi MI, Imran MK, Henkel RR. Standardised water-soluble extract of Eurycoma longifolia, Tongkat ali, as testosterone booster for managing men with late-onset hypogonadism? Andrologia. 2012 May;44 Suppl 1:226-30. doi: 10.1111/j.1439-0272.2011.01168.x. Epub 2011 Jun 15.</citation>
    <PMID>21671978</PMID>
  </reference>
  <reference>
    <citation>Tep-Areenan P, Sawasdee P, Randall M. Possible mechanisms of vasorelaxation for 5,7-dimethoxyflavone from Kaempferia parviflora in the rat aorta. Phytother Res. 2010 Oct;24(10):1520-5. doi: 10.1002/ptr.3164.</citation>
    <PMID>20878704</PMID>
  </reference>
  <reference>
    <citation>Wannanon P, Wattanathorn J, Tong-Un T et al. Efficacy Asssessment of Kaempferia Parviflora for the Management of Erectile Dysfunction. OnLine Journal of Biological Sciences. 12 (4), 149-155, 2012</citation>
  </reference>
  <reference>
    <citation>Wattanapitayakul SK, Suwatronnakorn M, Chularojmontri L, Herunsalee A, Niumsakul S, Charuchongkolwongse S, Chansuvanich N. Kaempferia parviflora ethanolic extract promoted nitric oxide production in human umbilical vein endothelial cells. J Ethnopharmacol. 2007 Apr 4;110(3):559-62. Epub 2006 Oct 13.</citation>
    <PMID>17113256</PMID>
  </reference>
  <reference>
    <citation>Wattanathorn J, Muchimapura S, Tong-Un T, Saenghong N, Thukhum-Mee W, Sripanidkulchai B. Positive Modulation Effect of 8-Week Consumption of Kaempferia parviflora on Health-Related Physical Fitness and Oxidative Status in Healthy Elderly Volunteers. Evid Based Complement Alternat Med. 2012;2012:732816. doi: 10.1155/2012/732816. Epub 2012 Jul 31.</citation>
    <PMID>22899957</PMID>
  </reference>
  <reference>
    <citation>Wattanathorn J, Pangphukiew P, Muchimapura S et al Aphrodisiac Activity of Kaempferia parviflora. American Journal of Agricultural and Biological Sciences. 7(2);114-120, 2012</citation>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">January 4, 2018</study_first_posted>
  <last_update_submitted>December 26, 2017</last_update_submitted>
  <last_update_submitted_qc>December 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Male sexual health</keyword>
  <keyword>Erectile function</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

